| Christopher D Robison, OD | |
|
291 N Milwaukee St Ste A-3, Boise, ID 83704-9132 | |
| (208) 378-7020 | |
| Not Available |
| Full Name | Christopher D Robison |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | 291 N Milwaukee St Ste A-3, Boise, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508550898 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | ODP-100624 (Idaho) | Primary |
| Provider Name | Lwk P C |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1851624019 PECOS PAC ID: 5890824247 Enrollment ID: O20100524000915 |
News Archive
A new study, presented at the European Society of Hypertension meeting in London, shows that vitamin D supplementation in winter can help lower blood pressure in patients with hypertension.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis).
Nearly 1,000 research abstracts will be presented on new and emerging obesity treatments, the science of weight loss, new prevention strategies, metabolic surgery, digital health technology and public policy when thousands of leading researchers, policymakers and health professionals gather for ObesityWeek 2015 at the Los Angeles Convention Center in California from November 2 - 7, 2015.
Contrary to what most people believe, the tendency to be prejudiced is a form of common sense, hard-wired into the human brain through evolution as an adaptive response to protect our prehistoric ancestors from danger.
› Verified 4 days ago
| Provider Name | Eye Pros Treasure Valley |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1083370340 PECOS PAC ID: 5496129934 Enrollment ID: O20230323000918 |
News Archive
A new study, presented at the European Society of Hypertension meeting in London, shows that vitamin D supplementation in winter can help lower blood pressure in patients with hypertension.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis).
Nearly 1,000 research abstracts will be presented on new and emerging obesity treatments, the science of weight loss, new prevention strategies, metabolic surgery, digital health technology and public policy when thousands of leading researchers, policymakers and health professionals gather for ObesityWeek 2015 at the Los Angeles Convention Center in California from November 2 - 7, 2015.
Contrary to what most people believe, the tendency to be prejudiced is a form of common sense, hard-wired into the human brain through evolution as an adaptive response to protect our prehistoric ancestors from danger.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher D Robison, OD 4719 W Santa Fe Ln, Meridian, ID 83642-8539 Ph: (208) 270-4917 | Christopher D Robison, OD 291 N Milwaukee St Ste A-3, Boise, ID 83704-9132 Ph: (208) 378-7020 |
News Archive
A new study, presented at the European Society of Hypertension meeting in London, shows that vitamin D supplementation in winter can help lower blood pressure in patients with hypertension.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis).
Nearly 1,000 research abstracts will be presented on new and emerging obesity treatments, the science of weight loss, new prevention strategies, metabolic surgery, digital health technology and public policy when thousands of leading researchers, policymakers and health professionals gather for ObesityWeek 2015 at the Los Angeles Convention Center in California from November 2 - 7, 2015.
Contrary to what most people believe, the tendency to be prejudiced is a form of common sense, hard-wired into the human brain through evolution as an adaptive response to protect our prehistoric ancestors from danger.
› Verified 4 days ago
Vision Quest Medical Center, Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5680 W Gage St, Boise, ID 83706 Phone: 208-377-3937 Fax: 208-377-9455 | |
Dr. Gregory N Bodily, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 610 Americana Blvd, Boise, ID 83702 Phone: 208-344-2020 Fax: 208-344-2371 | |
Brent Sexauer, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1175 W Boise Ave, Boise, ID 83706 Phone: 208-384-9194 | |
J. Randall Pitman & Associates, P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 2051 S Cole Rd, Boise, ID 83709 Phone: 208-672-1200 Fax: 208-321-8728 | |
Dr. James W Vail, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3417 N Cole Rd, Boise, ID 83704 Phone: 208-377-1102 Fax: 208-377-5853 | |
Dr. Lavar W Kofoed, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 291 N Milwaukee St, Boise, ID 83704 Phone: 208-378-7020 Fax: 208-378-9460 | |
Dr. Paul Christian Neville, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 305 E Jefferson St, Boise, ID 83712 Phone: 208-381-6910 |